PMV Pharmaceuticals, Inc.
PMVPHealthcare|Biotechnology|US
$1.26
-0.01 (-1.18%)
DCF Value
$0.65
Tangible Book / Share
$1.34
Cash / Share
$1.49
Financials
Financial Snapshot
Market Cap
$67.2M
Enterprise Value
$54.9M
Revenue (TTM)
$0.00
Net Income (TTM)
-$75.2M
Cash & Investments
$79.4M
Net Cash
$79.2M
Free Cash Flow (TTM)
-$71.3M
Operating CF (TTM)
-$71.3M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$79.4M
Quarterly Burn
$17.8M
Monthly Burn
$5.9M
Est. Runway
~4.5 quarters
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $61.9M | $101.5M | $361.4M | $297.2M | $241.1M | $203.1M | $169.5M | $112.9M | $79.4M | |
| Operating Cash Flow | -$15.2M | -$22.1M | -$32.7M | -$46.6M | -$63.8M | -$55.7M | -$51.3M | -$73.6M | -$71.3M | |
| Free Cash Flow | -$15.6M | -$22.2M | -$32.9M | -$47.9M | -$71.7M | -$56.6M | -$51.9M | -$73.6M | -$71.3M | |
| Capital Expenditure | -$452.0K | -$109.0K | -$148.0K | -$1.3M | -$8.0M | -$962.0K | -$655.0K | -$29.0K | -$14.0K | |
| Financing Cash Flow | $0.00 | $61.8M | $293.0M | $2.0M | $958.0K | $35.6M | $313.0K | $505.0K | $535.0K |
R&D Spending
R&D (TTM)
$64.0M
R&D Intensity
—
R&D Growth vs Prior
-8.4%
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $13.9M | $20.8M | $23.6M | $36.2M | $51.7M | $54.6M | $57.4M | $69.9M | $64.0M | |
| SG&A | $5.0M | $5.5M | $11.0M | $20.8M | $24.7M | $24.2M | $26.9M | $16.3M | $15.6M |
Income Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $338.0K | $388.0K | $318.0K | $1.3M | $650.0K | $1.3M | $1.1M | $0.00 | $34.0K | |
| Gross Profit | -$338.0K | -$388.0K | -$318.0K | -$1.3M | -$650.0K | -$1.3M | -$1.1M | $0.00 | -$34.0K | |
| R&D | $13.9M | $20.8M | $23.6M | $36.2M | $51.7M | $54.6M | $57.4M | $69.9M | $64.0M | |
| SG&A | $5.0M | $5.5M | $11.0M | $20.8M | $24.7M | $24.2M | $26.9M | $16.3M | $15.6M | |
| Operating Income | -$18.9M | -$26.6M | -$34.9M | -$58.3M | -$77.0M | -$80.1M | -$85.4M | -$86.2M | -$79.7M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$17.5M | -$25.3M | -$34.4M | -$57.8M | -$73.3M | -$69.0M | -$74.8M | -$79.9M | -$75.2M | |
| Net Income | -$17.5M | -$25.4M | -$34.4M | -$57.8M | -$73.3M | -$69.0M | -$58.7M | -$77.7M | -$75.2M | |
| EPS (Diluted) | -5.80 | -0.59 | -2.40 | -1.28 | -1.61 | -1.44 | -1.14 | -1.48 | -1.42 | |
| EBITDA | -$18.6M | -$25.0M | -$34.1M | -$57.5M | -$73.0M | -$67.7M | -$73.7M | -$79.8M | -$75.9M | |
| Shares Out. (M) | 3.02 | 43.00 | 44.78 | 45.14 | 45.59 | 48.01 | 51.58 | 52.54 | 53.39 |
Balance Sheet
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $30.3M | $73.3M | $361.4M | $172.5M | $108.3M | $37.7M | $40.9M | $38.0M | $12.5M | |
| Short-Term Investments | $31.6M | $28.2M | $0.00 | $124.7M | $132.8M | $165.4M | $128.6M | $75.0M | $67.0M | |
| Total Current Assets | $62.2M | $102.1M | $364.8M | $301.3M | $247.0M | $207.4M | $175.7M | $115.2M | $81.4M | |
| Total Assets | $63.5M | $103.0M | $365.5M | $331.6M | $270.3M | $252.2M | $191.3M | $116.6M | $82.1M | |
| Total Current Liabilities | $2.3M | $4.5M | $6.4M | $12.2M | $10.8M | $14.0M | $14.4M | $11.4M | $10.6M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $435.0K | $0.00 | |
| Total Liabilities | $109.6M | $173.5M | $6.4M | $23.0M | $24.3M | $26.5M | $15.2M | $11.8M | $10.6M | |
| Stockholders' Equity | -$46.1M | -$70.5M | $359.1M | $308.6M | $246.0M | $225.7M | $176.1M | $104.7M | $71.5M | |
| Retained Earnings | -$50.1M | -$75.4M | -$109.9M | -$167.7M | -$241.0M | -$310.0M | -$368.7M | -$446.5M | -$482.6M |
Cash Flow Statement
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$15.2M | -$22.1M | -$32.7M | -$46.6M | -$63.8M | -$55.7M | -$51.3M | -$73.6M | -$71.3M | |
| Capital Expenditure | -$452.0K | -$109.0K | -$148.0K | -$1.3M | -$8.0M | -$962.0K | -$655.0K | -$29.0K | -$14.0K | |
| Free Cash Flow | -$15.6M | -$22.2M | -$32.9M | -$47.9M | -$71.7M | -$56.6M | -$51.9M | -$73.6M | -$71.3M | |
| Investing Cash Flow | $21.7M | $3.2M | $27.9M | -$143.6M | -$1.4M | -$50.5M | $53.4M | $70.2M | $39.1M | |
| Financing Cash Flow | $0.00 | $61.8M | $293.0M | $2.0M | $958.0K | $35.6M | $313.0K | $505.0K | $535.0K | |
| Issuance of Stock | $0.00 | $0.00 | $223.2M | $2.0M | $958.0K | $35.1M | $313.0K | $505.0K | $535.0K | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $1.1M | $908.0K | $1.9M | $5.3M | $10.2M | $12.4M | $8.9M | $5.9M | $5.7M | |
| Net Change in Cash | $6.5M | $43.0M | $288.1M | -$188.1M | -$64.2M | -$70.6M | $2.3M | -$2.9M | -$31.7M |
Dilution Tracker
Shares Outstanding
53M
5-Year Share Growth
+17.3%
Stock Issuance (TTM)
$535.0K
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 3.02 | 43.00 | 44.78 | 45.14 | 45.59 | 48.01 | 51.58 | 52.54 | 53.39 | |
| Change vs Prior % | — | 1321.9% | 4.1% | 0.8% | 1.0% | 5.3% | 7.4% | 1.9% | 1.6% | |
| Stock Issuance | $0.00 | $0.00 | $223.2M | $2.0M | $958.0K | $35.1M | $313.0K | $505.0K | $535.0K | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $1.1M | $908.0K | $1.9M | $5.3M | $10.2M | $12.4M | $8.9M | $5.9M | $5.7M |
Margins & Profitability
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | 38.0% | 36.0% | -9.6% | -18.7% | -29.8% | -30.6% | -33.3% | -74.2% | -78.1% | |
| ROA % | -27.6% | -24.6% | -9.4% | -17.4% | -27.1% | -27.3% | -30.7% | -66.7% | -91.7% | |
| ROIC % | -30.9% | -27.0% | -9.7% | -18.2% | -29.6% | -33.5% | -37.8% | -79.5% | -111.1% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | -14.8% | 18.0% | -302.8% | 49.3% | -93.4% | 9.0% | 100.0% | |
| Operating Income | 0.0% | -41.0% | -31.2% | -66.8% | -32.2% | -4.0% | -6.6% | -0.9% | |
| Net Income | 0.0% | -44.6% | -35.8% | -68.0% | -26.7% | 5.9% | 14.9% | -32.4% | |
| EPS (Diluted) | 0.0% | 89.8% | -306.8% | 46.7% | -25.8% | 10.6% | 21.0% | -30.0% | |
| Operating Cash Flow | 0.0% | -45.4% | -48.4% | -42.2% | -36.9% | 12.7% | 7.9% | -43.5% | |
| Free Cash Flow | 0.0% | -41.9% | -48.3% | -45.7% | -49.7% | 21.1% | 8.3% | -41.7% | |
| R&D Expense | 0.0% | 49.9% | 13.8% | 53.2% | 42.8% | 5.7% | 5.0% | 21.8% | |
| SG&A Expense | 0.0% | 9.0% | 100.5% | 89.2% | 18.7% | -1.9% | 11.0% | -39.3% | |
| Total Assets | 0.0% | 62.4% | 254.8% | -9.3% | -18.5% | -6.7% | -24.1% | -39.1% | |
| Book Value / Share | 0.0% | 89.3% | 589.3% | -14.8% | -21.1% | -12.9% | -27.4% | -41.6% | |
| Debt | 0.0% | -100.0% | 0.0% | 0.0% | 24.9% | -4.9% | -91.0% | -29.6% | |
| Diluted Shares | 0.0% | 1321.9% | 4.1% | 0.8% | 1.0% | 5.3% | 7.4% | 1.9% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.94
10Y Low / Med / High0.44 / 1.61 / 7.67
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.65
Tangible Book / Share
$1.34
Net Current Assets / Share
$1.33
Graham Net-Net
$1.29
Cash / Share
$1.49
| Metric | Trend | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -6.47 | -63.58 | -25.63 | -18.05 | -5.40 | -2.15 | -1.33 | -0.84 | -0.89 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -2.46 | -22.89 | 7.67 | 3.38 | 1.61 | 0.66 | 0.44 | 0.63 | 0.94 | |
| EV/EBITDA | -10.26 | -61.69 | -70.14 | -15.32 | -4.14 | -1.84 | -0.52 | -0.36 | -0.72 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-6.44
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $2.9M | $6.2M | $30.1M |
| Net Income | -$59.0M | -$42.7M | -$37.6M |
| EPS | $-1.13 | $-0.81 | $-0.71 |
| # Analysts (EPS) | 2 | 2 | 2 |